Overview

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma

Status:
Completed

Trial end date:
2020-03-25

Target enrollment:

Participant gender:

Summary

This is an open-label, multicenter, Phase Ib, dose-escalation and cohort-expansion study of atezolizumab (anti-programmed death-ligand 1 [PD-L1] antibody) in combination with vemurafenib or vemurafenib plus cobimetinib in participants with BRAFV600-mutation positive metastatic melanoma. Enrolled participants may continue treatment until they are no longer experiencing clinical benefit as assessed by the investigator and in alignment with the protocol.

Phase:

Phase 1

Details

Lead Sponsor:

Genentech, Inc.

Treatments:

Antibodies
Antibodies, Monoclonal
Atezolizumab
Vemurafenib